Previous 10 | Next 10 |
AVEO Pharmaceuticals (NASDAQ:AVEO): Q2 GAAP EPS of -$0.40 beats by $0.10. Revenue of $7.6M (+913.3% Y/Y) beats by $0.64M. AVEO believes its $102.9M in cash, cash equivalents and marketable securities as of June 30, 2021, along with expected net product revenues from the commercial launch of F...
– Total 2Q 2021 Revenue of $7.6 Million Includes FOTIVDA ® (tivozanib) U.S. Net Product Revenue of $6.7 Million – – Pivotal Phase 3 TiNivo-2 Trial of FOTIVDA in Combination with OPDIVO ® (nivolumab) on Track to Initiate Enrollment in ...
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021. AVEO’s management team will host a conference call and audio webcast at 4:3...
AVEO’s lead drug candidate, Tivozanib, recently got U.S. FDA approval for treatment of Renal Cell Carcinoma. It clocked in revenue of $1.1 Million within just nine days of getting approved. Besides Tivozanib, AVEO is working on four other major drug candidates that will help in...
Webinar on Friday, July 16 th at 12 p.m. Eastern Time FOTIVDA recently surpassed 300 total commercial prescriptions since its March 22, 2021 launch AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announce...
At the conclusion of the 2021 Russell indexes annual reconstitution following notable healthcare stocks will join the Russell 3000 Index, effective June 28 after the U.S. market opens.Bionano Genomics (BNGO), Asensus Surgical (ASXC), Ocugen (OCGN), Senseonics Holdings (SEN...
AVEO Oncology has had a transformational 2021 thus far. The company's flagship product, FOTIVDA, has finally been approved in advanced RCC and was subsequently launched into a relatively unclaimed market. The company reported their Q1 earnings that revealed that FOTIVDA is already gai...
Webinar on Wednesday, June 16 at 2:00 p.m. Eastern Time AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader webinar focusing on ficlatuzumab, the Company’s investig...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
- Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up - - Analysis of TEAEs in TIVO-3 Study Shows Longer Time to Onset and Fewer Dose Reductions for TEAEs for Tivozanib Comp...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...